by no longer screening patients in these two categories. Our results, however, question the validity of screening to protect dentists. A more logical approach would be to encourage vaccination of all staff at risk of infection with HBV at the earliest possible opportunity and to assume that all patients are a potential source of infection. We have recently adopted this policy.
Does nifedipine ameliorate cyclosporin A nephrotoxicity?
Nephrotoxicity is a serious disadvantage of cyclosporin A and may lead to irreversible loss ofrenal function.' Recent evidence suggests that it may be a haemodynanic phenomenon due to intrarenal vasoconstriction.2 3 Studies in animals show that the calcium channel blocker nifedipine may reverse the effects of long term treatment with cyclosporin.4 We report the influence of nifedipine on graft function in a retrospective study of renal transplant recipients given cyclosporin.
Patients, methods, and results
We reviewed 106 patients who had stable transplant function at least three months after grafting and were taking cyclosporin. Cyclosporin (usually combined with low dose prednisolone) was given in maintenance doses of 5-8 mg/kg/day, and trough whole blood cyclosporin concentrations were measured by high pressure liquid chromatography. Renal function was assessed by measuring the serum creatinine value. Hypertension (diastolic blood pressure 195 mm Hg requiring drug treatment) was usually treated by f3 blockers combined with vasodilators; since 1984 prazosin and hydralazine had increasingly been superseded by nifedipine. Choice of blood pressure treatment was based on individual clinical decision. All rejection episodes had been confirmed histologically.
Hypertension was present in 90 (85%) of the patients taking cyclosporin (compared with 54% of our patients receiving azathioprine; p<0-001). For further analysis patients receiving nifedipine (n=58) were separated from those who were hypertensive but not taking nifedipine (n=32) and from the normotensive group (n= 16) (table). The three groups did not differ in distribution of primary renal disease leading to end stage renal failure, incidence of bilateral nephrectomy, and use of prednisolone.
Those receiving nifedipine had their grafts for a shorter mean period (p<0-00l), which was reflected in a significantly higher mean dose ofcyclosporin (p<0-02) and higher whole blood concentrations of the drug (p<0-05). Despite this, renal function was better in those receiving nifedipine compared with hypertensive patients not receiving nifedipine (serum creatinine concentration 153 (SEM 10) v 183 (13) Mmol/l; p<005) and similar to that in normotensive patients taking cyclosporin (154 (11) timol/l). Blood pressure was controlled to an equivalent, acceptable degree in both hypertensive groups.
Rejection was infrequent during treatment with cyclosporin, only 33 of the 106 patients having suffered a rejection episode. More patients in group 2 had suffered rejection episodes (14/32; 43-8%) compared with group 3 (15/58; 25-9%) and group 1 (4/16; 25%) (p<005). Analysis of the 71 patients who had never had a rejection episode, however, showed that the serum creatinine concentration among those receiving nifedipine was still lower than in hypertensive patients not receiving nifedipine (141 (6 8) v 175 (22) ,umol/l; p<0O05) and comparable to that in normotensive patients.
Comment
This retrospective analysis has identified a cohort of renal transplant recipients receiving nifedipine for cyclosporin related hypertension who, owing to shorter graft duration, high cyclosporin dosage, and higher blood concentrations of cyclosporin, would have been at risk. of more severe cyclosporin nephrotoxicity. These patients, however, had better graft function than equivalent hypertensive patients receiving other drug treatment. This finding was sustained even when the possible influence of previous graft rejection was excluded.
Though cyclosporin may produce irreversible loss of renal function,' the more characteristic pattern of a raised serum creatinine concentration rapidly falling when cyclosporin dosage is reduced suggests a haemodynamic abnormality. Studies in rodents suggest that cyclosporin produces intrarenal vasoconstriction,2 and isotope studies in patients with renal transplants have shown increased renal vascular resistance which is corrected with a parallel fall in serum creatinine concentration when cyclosporin is replaced by azathioprine.3
The role of vasodilator agents to reverse cyclosporin nephrotoxicity has not been studied in man. Animal studies suggest that nifedipine is superior to a adrenergic blockade, converting enzyme inhibition, and manipulation of prostaglandins in reversing cyclosporin induced intrarenal vasoconstriction.4 It is not clear if this is a specific effect ofcalcium channel blockade, though there is some evidence that calcium channel blockers prevent cyclosporin uptake by kidney cells in culture.5
Nifedipine appears to be of potential value as a cyclosporin nephroprotective agent, and further prospective haemodynamic studies are justified.
